The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sanjay Nannapaneni

NATCOPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.6%1-day move

₹960.00

prior close

₹990.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-2.7-3.1-3.0-2.7-1.6+0.1-1.6+0.2-3.5+1.2+17.5+12.9+21.9-11.3

Up moveDown movePending

AI summary

Sanjay Nannapaneni, a member of Natco Pharma's promoter group, sold 70,000 equity shares in the open market between 9 March and 10 March 2026 for an approximate value of Rs. 7.12 crore. His holding dropped from 2,26,910 shares (0.13%) to 1,56,910 shares (0.09%) of the company. The disclosure was filed under SEBI's insider trading and takeover regulations, and no shares were encumbered, pledged, or transferred off-market. Natco Pharma's total equity share capital remains unchanged at approximately 17.91 crore shares of Rs. 2 each.

Likely market impact

The sale size is very small at just 0.04% of total share capital, so it is unlikely to materially affect the stock price or promoter control. Retail investors should view this as a routine, minor trim by a promoter group member and not a signal of distress or a strategic shift.